Anti-PD−1 immunotherapy has emerged as a breakthrough cancer therapy that functions to block programmed cell death protein 1 (PD−1) on the surface of CD8+ T cells or its partner ligand PD-L1 on tumor cells, allowing cytotoxic T cells to sustain antitumor activity.144. This evidence concerns the gene CD8A and cancer.